SCHEMBL2403715

SCHEMBL2403715

CCOc1ccc(N2CCN(Cc3nc(-c4ccc(C(F)(F)F)cc4)sc3CSc3ccc(OC(C)(C)C(=O)O)cc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 18/20 0.57
PPARD Q03181 17/20 0.57
PPARG P37231 7/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4808451 0.93 PPARA (0.59) PPARAPPARDPPARG
SCHEMBL4810762 0.92 PPARA (0.61) PPARAPPARDPPARG
SCHEMBL4808137 0.91 PPARA (0.57) PPARAPPARDPPARG
SCHEMBL4813025 0.89 PPARA (0.53) PPARAPPARDPPARG
SCHEMBL4815199 0.88 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL4850099 0.87 PPARA (0.52) PPARAPPARDPPARG
SCHEMBL4804485 0.87 PPARA (0.48) PPARAPPARDPPARG
SCHEMBL4806547 0.87 PPARA (0.49) PPARAPPARDPPARG
SCHEMBL4812232 0.87 PPARA (0.49) PPARAPPARDPPARG
SCHEMBL4809628 0.86 PPARA (0.47) PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224264-A1 MEDICAMENTS BROWN KATHLEEN KEATING 2011-09-15 US disclosed
US-20110224264-A1 MEDICAMENTS BROWN KATHLEEN KEATING 2011-09-15 US disclosed
US-20110224264-A1 MEDICAMENTS BROWN KATHLEEN KEATING 2011-09-15 US disclosed
US-20100280080-A1 Medicaments BROWN KATHLEEN KEATING 2010-11-04 US disclosed
US-20100280080-A1 Medicaments BROWN KATHLEEN KEATING 2010-11-04 US disclosed
US-7767682-B2 Medicaments GLAXOSMITHKLINE LLC (US) 2010-08-03 US disclosed
US-7767682-B2 Medicaments GLAXOSMITHKLINE LLC (US) 2010-08-03 US disclosed
US-7767682-B2 Medicaments GLAXOSMITHKLINE LLC (US) 2010-08-03 US disclosed
US-20080113996-A1 Medicaments SMITHKLINE BEECHAM CORPORATION (US) 2008-05-15 US disclosed
US-20080113996-A1 Medicaments SMITHKLINE BEECHAM CORPORATION (US) 2008-05-15 US disclosed
EP-1853258-A4 MEDICAMENTS SMITHKLINE BEECHAM CORP (US) 2008-05-07 EP disclosed
EP-1853258-A2 MEDICAMENTS SmithKline Beecham Corporation (US) 2007-11-14 EP disclosed
WO-2006096398-A2 MEDICAMENTS SMITHKLINE BEECHAM CORPORATION (US) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224264-A1 MEDICAMENTS GLS, PKD1, ATP6V1B1 PPARA 4/4885PPARD 7/4885PPARG 6/4885
US-20080113996-A1 Medicaments GLS, PKD1, ATP6V1B1 PPARA 4/4885PPARD 7/4885PPARG 6/4885
US-20100280080-A1 Medicaments GLS, PKD1, ATP6V1B1 PPARA 4/4885PPARD 7/4885PPARG 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.